Table of Contents

Experimental Evidence

Driver mutations affecting this gene in DLBCL have been experimentally demonstrated to cause a reduction or loss of function (LOF).

Relevance tier by entity

Entity Tier Description
BL 2 Role of TNFRSF14 mutations in BL requires confirmation
DLBCL 1 High-confidence DLBCL gene
FL 1 High-confidence FL gene
MZL 1 High-confidence MZL gene

Mutation incidence in large patient cohorts (GAMBL reanalysis)

DLBCL

Entity Collection N mutated Incidence 95% CI
DLBCL GAMBL without Reddy 1,089 165 0.1515 [0.1302,0.1728]
DLBCL GAMBL with Reddy 2,088 262 0.1255 [0.1113,0.1397]
DLBCL BC 231 36 0.1558 [0.1091,0.2026]
DLBCL Dana-Farber 303 40 0.1320 [0.0939,0.1701]
DLBCL NCI 470 79 0.1681 [0.1343,0.2019]
DLBCL Reddy 999 97 0.0971 [0.0787,0.1155]
DLBCL DLBCL_ICGC 85 10 0.1176 [0.0492,0.1861]

FL

pathology Collection N mutated Incidence CI
FL GAMBL without Crouch 642 260 0.4050 [0.367,0.443]
FL GAMBL with Crouch 1,189 524 0.4407 [0.4125,0.4689]
FL BC 379 146 0.3852 [0.3362,0.4342]
FL Kalmbach 164 77 0.4695 [0.3931,0.5459]
FL Crouch 547 264 0.4826 [0.4408,0.5245]
FL FL_ICGC 99 37 0.3737 [0.2784,0.469]

Mutation pattern and selective pressure estimates

Entity Missense dN/dS Nonsense dN/dS Q value
BL 1.9974 24.5966 1
FL 37.0958 411.8990 0
DLBCL 3.8379 22.1471 0

TNFRSF14 Hotspots

Chromosome Coordinate (hg19) ref>alt HGVSp
chr1 2488104 A>G M1?
chr1 2488105 T>C M1?
chr1 2488105 T>G M1?
chr1 2488106 G>A M1?
chr1 2488107 G>T E2*
chr1 2488123 G>A W7*
chr1 2488124 G>A W7*
chr1 2488132 C>A P10H
chr1 2488138 G>A W12*
chr1 2488139 G>A W12*
chr1 2488152 A>T K17*
chr1 2488156 C>A T18N

Visualizations

Protein

View coding variants in ProteinPaint hg19 or hg38

Genome

View all variants in GenomePaint hg19 or hg38

Expression

History

%%{init: { 'logLevel': 'debug', 'theme': 'dark' } }%% timeline title Publication timing 2010-11-15 : Cheung : FL 2011-07-27 : Morin : DLBCL 2012-03-06 : Lohr : DLBCL 2013-01-01 : Zhang : DLBCL 2013-08-15 : Morin : DLBCL 2016-09-08 : Spina : MZL

References

1.
Cheung KJJ, Johnson NA, Affleck JG, Severson T, Steidl C, Ben-Neriah S, Schein J, Morin RD, Moore R, Shah SP, Qian H, Paul JE, Telenius A, Relander T, Lam W, Savage K, Connors JM, Brown C, Marra MA, Gascoyne RD, Horsman DE. Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis. Cancer Res. 2010 Nov 15;70(22):9166–9174.
2.
Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, Johnson NA, Severson TM, Chiu R, Field M, Jackman S, Krzywinski M, Scott DW, Trinh DL, Tamura-Wells J, Li S, Firme MR, Rogic S, Griffith M, Chan S, Yakovenko O, Meyer IM, Zhao EY, Smailus D, Moksa M, Chittaranjan S, Rimsza L, Brooks-Wilson A, Spinelli JJ, Ben-Neriah S, Meissner B, Woolcock B, Boyle M, McDonald H, Tam A, Zhao Y, Delaney A, Zeng T, Tse K, Butterfield Y, Birol I, Holt R, Schein J, Horsman DE, Moore R, Jones SJM, Connors JM, Hirst M, Gascoyne RD, Marra MA. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011 Jul 27;476(7360):298–303. PMCID: PMC3210554
3.
Spina V, Khiabanian H, Messina M, Monti S, Cascione L, Bruscaggin A, Spaccarotella E, Holmes AB, Arcaini L, Lucioni M, Tabbò F, Zairis S, Diop F, Cerri M, Chiaretti S, Marasca R, Ponzoni M, Deaglio S, Ramponi A, Tiacci E, Pasqualucci L, Paulli M, Falini B, Inghirami G, Bertoni F, Foà R, Rabadan R, Gaidano G, Rossi D. The genetics of nodal marginal zone lymphoma. Blood. 2016 Sep 8;128(10):1362–1373. PMCID: PMC5016706

Citing

If you use the information or data from this site, please cite

Krysta Coyle, Kostiantyn Dreval, Daniel Hodson and Ryan D. Morin. Audit of B-cell cancer genes. Blood Adv (2025) 9 (8): 2019–2031.

Disclaimer

The content in these pages has been populated, in part, by an automated process. Although we have scrutinized every page to ensure accuracy, errors will inevitably exist. If you find an error please report it as an issue and we will address it.

License

This work is licensed under a Creative Commons Attribution 4.0 International License.

You are free to:

Share — copy and redistribute the material in any medium or format for any purpose, even commercially.

Adapt — remix, transform, and build upon the material for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms.